---
schema_version: "secwatch.filing_event.v1"
accession: "0001607062-24-000150"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2024-04-29T23:59:59+00:00"
generated_at: "2026-06-03T05:33:27.019315+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma issues 20,068 Series A Preferred shares for consulting; amends sublease

## Summary
- Issued 20,068 Series A Preferred shares to Value Quest Inc. for one-year social media consulting services.
- Consulting covers Facebook and Twitter management; shares are unregistered restricted securities.
- Amended sublease with BST Partners (controlled by CEO David Koos) to reimburse shared expenses in addition to $5k/month base rent.
- Subtenant also required to pay shared expenses retroactive to January 1, 2024, per amendment.
- Both transactions involve related party: David Koos is CEO and also controls BST Partners.

## SEC filing metadata
- accession: 0001607062-24-000150
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2024-04-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.01, 8.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000160706224000150/0001607062-24-000150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000160706224000150/rgbp042924form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607062-24-000150
- JSON: https://secwatch.observer/filing/0001607062-24-000150.json
- Plain text: https://secwatch.observer/filing/0001607062-24-000150.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.